Kidney donation is becoming increasingly common throughout the world, with the United States and Japan leading the way in this field, and the studies referenced in this Newsletter came from these two countries.
SCOR's 2012 renewals.
SCOR Global P&C has recorded a very satisfactory increase in its business in 2011: gross written premiums are up by 8.8% to EUR 3.982 billion at current exchange rates.
SCOR Global P&C has recorded a very satisfactory increase in its business in 2011: gross written premiums are up by 8.8% to EUR 3.982 billion at current exchange rates.
SCOR successfully concludes the January 1, 2012 renewals: 13.9% growth, satisfactory pricing conditions (+2%) and expected technical profitability
SCOR successfully concludes the January 1, 2012 renewals: 13.9% growth, satisfactory pricing conditions (+2%) and expected technical profitability.
In my role as a Research Actuary, I am often asked to perform mortality experience studies using the SOA 2001 Valuation Basic Tables (VBT) as an expected basis.
Life insurers are cautious about integrating medical and technological advances into their underwriting procedures in order to avoid unintended consequences to decision accuracy.
The Continuous Mortality Investigation (CMI) has recently published Working Papers 52 and 58. These Papers represent a third phase in the activity of the CMI Critical Illness Committee.
SCOR successfully places on the Swiss franc market perpetual subordinated notes, with a first call date in August 2016, for an aggregate total amount of CHF 400,000,000.
SCOR successfully places on the Swiss franc market perpetual subordinated notes, with a first call date in August 2016, for an aggregate total amount of CHF 400,000,000.
Details about the liquidity account at 31 December 2011 and of the last half-year statement.
